Andelyn Biosciences, a contract development and manufacturing organization (CDMO) focused on cell and gene therapy, has secured a license agreement with the Broad Institute to incorporate MyoAAV plasmids into its AAV Curator Platform.
 
Developed by Broad Institute researchers, MyoAAV plasmids produce adeno-associated viruses (AAVs) that exhibit ten times greater efficiency in targeting muscle tissue compared to traditional vectors while simultaneously reducing liver targeting. This enhanced specificity could potentially lower the required dosage for gene therapies.
 
Through this agreement, Andelyn will utilize MyoAAV plasmids to offer research and development services to clients developing gene therapies. These services encompass candidate screening, scale-up, preclinical development, and support for Investigational New Drug (IND) applications. Andelyn will also grant sublicensing rights to clients for internal research purposes.
 
The collaboration aims to accelerate the development of gene therapies for diseases with significant unmet medical needs. By leveraging MyoAAV technology, Andelyn seeks to improve product safety and reduce the overall drug dosage.
 
Matt Niloff, Chief Commercial Officer of Andelyn, said, “Our license from the Broad Institute furthers our goal of providing the industry access to critical tools and capabilities that facilitate the development of innovative therapies to bring more treatments to more patients. With access to the increased specificity of MyoAAVs, our clients now have the opportunity to maximize efficiency in their gene therapy processes and drive down the cost per patient.”

Related News